To the Editor:
We report the case of a 32-year-old Caucasian female patient with fistulizing Crohn's disease complicated by diversion colitis.
Due to therapy-refractory perianal fistulae, diverting sigmoidostomy had been performed in early 2016. Initially, the patient reported good general condition under vedolizumab therapy, although the fistulae persisted. In late 2016, she noticed looser stools, progressive lower abdominal pain, and passage of mucus and blood via the anus.
Suspecting a manifestation of Crohn's disease, treatment was switched to ustekinumab and, due to non-response, intermittent topical hydrocortisone application was needed. Subsequently, combination therapy with infliximab and 6-mercaptopurin was initiated. Again, there were no signs of therapeutic efficacy as clinical disease activity persisted.
Endoscopically, mucosal inflammation was evident in the distal ostomy branch (Fig. 1a) , while the proximal branch was unaffected. Histological evaluation revealed edematous mucosa with lymphoplasmocytic lamina propria infiltration and hyperplasia of local lymphatic tissue (Fig. 1b) . Together, these findings indicated the presence of diversion colitis [1] .
Reversal of sigmoidostomy was not a therapeutic option due to the persisting fistulae. Local therapy with 5-ASA and glucocorticoids had been ineffective. Intended local therapy with short-chain fatty acid (SCFA) enemas [2, 3] was not possible, as-to our knowledge-no pharmacological formulation of SCFAs is available [2] and we did not find any compounding pharmacy.
Therefore, and in view of the deteriorating condition of the patient, proctectomy was recommended, which was refused by the patient, who instead asked for an alternative conservative therapy. Thus, in agreement with the patient, daily local administration of 100 mL prewarmed coconut oil as a rectal enema was initiated.
This was based on the rationale that coconut oil contains fatty acids with comparatively short chain length [4] . Although these are not identical with the SCFAs established in diversion colitis therapy, they are commensally produced and reduced in the inflamed mucosa [5] suggesting a positive impact on epithelial metabolism as postulated for SCFAs [2] . Indeed, cell death studies with the colon epithelial cell line HT29 demonstrated that coconut oil, but not other oils exclusively consisting of fatty acids with long chain length [4] , substantially decreased epithelial cell necrosis (Fig. 2) . One week after initiation of daily coconut oil administrations, the patient reported decreasing abdominal pain and mucus secretion. After another 6 weeks of continuous therapy, hematochezia and mucus secretion had completely stopped. In a sigmoidoscopy performed after 8 weeks of daily therapy, clear improvement of endoscopic and histologic signs of inflammation could be observed. After 12 weeks of treatment, the patient was free of pain, back to work and physically active 3 to 4 times a week. Another follow-up endoscopy after 5 months confirmed stable disease with only low-grade inflammation. Similarly, histology verified maintained improvement. Daily coconut oil application has been continued by the patient for 6 months with continuous clinical response and without any adverse events. In the light of currently unavailable pharmacological formulations, local application of coconut oil can be considered as a treatment option in patients with severe refractory diversion colitis.
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